TRAX
NASDAQFirst Tracks Biotherapeutics Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
News25/Ratings9
News · 26 weeks72+1600%
2026-03-012026-08-23
Mix3290d
- Insider21(66%)
- Other5(16%)
- SEC Filings4(13%)
- Analyst2(6%)
Latest news
25 items- INSIDERSEC Form 4 filed by Chief Business Officer Stone Benjamin4 - First Tracks Biotherapeutics, Inc. (0002091349) (Issuer)
- INSIDERSEC Form 4 filed by President, CEO Faga Daniel4 - First Tracks Biotherapeutics, Inc. (0002091349) (Issuer)
- INSIDERSEC Form 4 filed by Chief Medical Officer Lizzul Paul F.4 - First Tracks Biotherapeutics, Inc. (0002091349) (Issuer)
- ANALYSTWolfe Research initiated coverage on First Tracks Biotherapeutics with a new price targetWolfe Research initiated coverage of First Tracks Biotherapeutics with a rating of Outperform and set a new price target of $83.00
- SECSEC Form SCHEDULE 13G filed by First Tracks Biotherapeutics Inc.SCHEDULE 13G - First Tracks Biotherapeutics, Inc. (0002091349) (Subject)
- SECSEC Form SCHEDULE 13G filed by First Tracks Biotherapeutics Inc.SCHEDULE 13G - First Tracks Biotherapeutics, Inc. (0002091349) (Subject)
- SECSEC Form 424B3 filed by First Tracks Biotherapeutics Inc.424B3 - First Tracks Biotherapeutics, Inc. (0002091349) (Filer)
- SECSEC Form 10-Q filed by First Tracks Biotherapeutics Inc.10-Q - First Tracks Biotherapeutics, Inc. (0002091349) (Filer)
- SECFirst Tracks Biotherapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - First Tracks Biotherapeutics, Inc. (0002091349) (Filer)
- PRFirst Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business UpdateCompleted enrollment for Cohort 1 (gluten challenge) of Phase 1b ANB033 trial in celiac disease (CeD); top-line Cohort 1 data reaffirmed for Q4 2026Cohort 2 (mucosal healing) enhanced to enroll up to 40 patients including those with a broad range of histologic (Vh:Cd ratio ≤ 2.5) and symptom severity to further inform future development; top-line Cohort 2 data anticipated in Q1 2027U.S. FDA granted Fast Track designation for ANB033 for the treatment of CeDEnrollment ongoing for Phase 1b ANB033 trial in eosinophilic esophagitis (EoE); top-line data anticipated in Q3 2027Reiterating cash-runway into Q2 2028, including the expansion of ANB033 into two additional indications in H1 2027 SAN DIEG
- INSIDERAmendment: SEC Form 3 filed by new insider Lizzul Paul F.3/A - First Tracks Biotherapeutics, Inc. (0002091349) (Issuer)
- INSIDERAmendment: SEC Form 3 filed by new insider Stone Benjamin3/A - First Tracks Biotherapeutics, Inc. (0002091349) (Issuer)
- INSIDERAmendment: SEC Form 3 filed by new insider Faga Daniel3/A - First Tracks Biotherapeutics, Inc. (0002091349) (Issuer)
- SECSEC Form SCHEDULE 13G filed by First Tracks Biotherapeutics Inc.SCHEDULE 13G - First Tracks Biotherapeutics, Inc. (0002091349) (Subject)
- INSIDERSEC Form 4 filed by Chief Business Officer Stone Benjamin4 - First Tracks Biotherapeutics, Inc. (0002091349) (Issuer)
- INSIDERSEC Form 4 filed by Chief Medical Officer Lizzul Paul F.4 - First Tracks Biotherapeutics, Inc. (0002091349) (Issuer)
- INSIDERSEC Form 4 filed by President, CEO Faga Daniel4 - First Tracks Biotherapeutics, Inc. (0002091349) (Issuer)
- SECSEC Form SCHEDULE 13G filed by First Tracks Biotherapeutics Inc.SCHEDULE 13G - First Tracks Biotherapeutics, Inc. (0002091349) (Subject)
- SECFirst Tracks Biotherapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement8-K - First Tracks Biotherapeutics, Inc. (0002091349) (Filer)
- INSIDERDirector Schmid John P. converted options into 6,030 shares, increasing direct ownership by 19% to 37,652 units (SEC Form 4)4 - First Tracks Biotherapeutics, Inc. (0002091349) (Issuer)
- INSIDERDirector Marquet Magda converted options into 6,030 shares, increasing direct ownership by 61% to 15,960 units (SEC Form 4)4 - First Tracks Biotherapeutics, Inc. (0002091349) (Issuer)
- INSIDERDirector Jain Rita converted options into 7,330 shares, increasing direct ownership by 62% to 19,194 units (SEC Form 4)4 - First Tracks Biotherapeutics, Inc. (0002091349) (Issuer)
- INSIDERDirector Orwin John A converted options into 6,030 shares, increasing direct ownership by 57% to 16,695 units (SEC Form 4)4 - First Tracks Biotherapeutics, Inc. (0002091349) (Issuer)
- INSIDERDirector Ware J. Anthony converted options into 6,030 shares, increasing direct ownership by 63% to 15,660 units (SEC Form 4)4 - First Tracks Biotherapeutics, Inc. (0002091349) (Issuer)
- INSIDERDirector Fenton Dennis M converted options into 6,030 shares, increasing direct ownership by 121% to 10,995 units (SEC Form 4)4 - First Tracks Biotherapeutics, Inc. (0002091349) (Issuer)
TRAX FAQ
5 questionsWhere does TRAX stock trade?
First Tracks Biotherapeutics Inc. (TRAX) is listed on NASDAQ.What sector and industry is TRAX in?
First Tracks Biotherapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about TRAX?
First Tracks Biotherapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Wolfe Research: Outperform on 2026-08-18. Recent price targets range from $3000.00 to $4600.00.What companies are similar to TRAX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare TRAX side-by-side with any of them on Quantisnow.How can I track TRAX on Quantisnow?
Quantisnow aggregates First Tracks Biotherapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TRAX to receive live email and push alerts on every new disclosure.